PTPRC and neoplasm: Since the enhanced anti-tumor effect of the DOX/ESTA combination was accompanied by a profound decrease in intratumoral CD45+ density, we next performed multicolor flow cytometry (FACS) to identify the affected immune cell subsets (Supplementary Figure S6).